STERIS Toekomstige groei
Future criteriumcontroles 1/6
STERIS zal naar verwachting groeien in winst en omzet met respectievelijk 11.5% en 6% per jaar. De winst per aandeel zal naar verwachting groeien met 11.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 11.6% zijn.
Belangrijke informatie
11.5%
Groei van de winst
11.6%
Groei van de winst per aandeel
| Medical Equipment winstgroei | 17.1% |
| Inkomstengroei | 6.0% |
| Toekomstig rendement op eigen vermogen | 11.6% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 18 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'
Nov 18What Does STERIS plc's (NYSE:STE) Share Price Indicate?
Oct 19
Is STERIS (NYSE:STE) A Risky Investment?
Oct 01Steris: Dental Divestiture, Surgical Instrumentation Acquisition, But Overvalued
Sep 16Earnings Tell The Story For STERIS plc (NYSE:STE)
Sep 13Steris: Q2 Numbers Solidify Buy Thesis
Aug 13STERIS plc's (NYSE:STE) Intrinsic Value Is Potentially 59% Above Its Share Price
Aug 08When Should You Buy STERIS plc (NYSE:STE)?
Jul 04Is STERIS (NYSE:STE) Using Too Much Debt?
Jun 13Steris: Moving On, Losing Its Teeth
Apr 14STERIS plc's (NYSE:STE) Intrinsic Value Is Potentially 31% Above Its Share Price
Mar 29STERIS (NYSE:STE) Has A Pretty Healthy Balance Sheet
Mar 07Steris: Strong Healthcare Products Growth Coupled With Weak AST Business
Feb 17STERIS plc's (NYSE:STE) Business Is Trailing The Industry But Its Shares Aren't
Feb 15An Intrinsic Calculation For STERIS plc (NYSE:STE) Suggests It's 23% Undervalued
Dec 17Should You Investigate STERIS plc (NYSE:STE) At US$203?
Nov 24Steris: Comprehensive Sterilization Portfolios Tailored To Procedure Volumes
Nov 08We Think STERIS (NYSE:STE) Can Stay On Top Of Its Debt
Nov 06Are STERIS plc (NYSE:STE) Investors Paying Above The Intrinsic Value?
Sep 18Steris: Remains On Track For Strong Fiscal '24, Added Upsides From Operating Leverage
Sep 01When Should You Buy STERIS plc (NYSE:STE)?
Aug 10Steris: Continuing To Grow The Product Lineup
Jun 20Steris falls 10% on Q3 revenue, profit miss, 2023 profit guidance lowered
Feb 09Steris declares $0.47 dividend
Feb 01These 4 Measures Indicate That STERIS (NYSE:STE) Is Using Debt Reasonably Well
Feb 01Calculating The Intrinsic Value Of STERIS plc (NYSE:STE)
Dec 28Steris declares $0.47 dividend
Nov 02STERIS (NYSE:STE) Seems To Use Debt Quite Sensibly
Nov 01Steris: Non-GAAP Valuations Supportive Of Substantial Upside
Sep 04STERIS (NYSE:STE) Will Pay A Larger Dividend Than Last Year At $0.47
Aug 18STERIS' (NYSE:STE) Dividend Will Be Increased To $0.47
Aug 04Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 3/31/2027 | 6,205 | 868 | 1,278 | 1,690 | 6 |
| 3/31/2026 | 5,841 | 773 | 1,104 | 1,328 | 9 |
| 3/31/2025 | 5,492 | 662 | 798 | 1,099 | 9 |
| 9/30/2024 | 5,326 | 591 | 680 | 1,101 | N/A |
| 6/30/2024 | 5,235 | 561 | 594 | 996 | N/A |
| 3/31/2024 | 5,139 | 551 | 613 | 973 | N/A |
| 12/31/2023 | 4,780 | 1,028 | 594 | 934 | N/A |
| 9/30/2023 | 4,601 | 1,012 | 535 | 849 | N/A |
| 6/30/2023 | 4,563 | 576 | 494 | 806 | N/A |
| 3/31/2023 | 4,536 | 557 | 395 | 757 | N/A |
| 12/31/2022 | 4,784 | -28 | 349 | 713 | N/A |
| 9/30/2022 | 4,777 | -8 | 399 | 752 | N/A |
| 6/30/2022 | 4,773 | 377 | 472 | 819 | N/A |
| 3/31/2022 | 4,223 | 285 | 397 | 685 | N/A |
| 12/31/2021 | 4,248 | 279 | 412 | 701 | N/A |
| 9/30/2021 | 3,848 | 250 | 400 | 662 | N/A |
| 6/30/2021 | 3,407 | 286 | 424 | 653 | N/A |
| 3/31/2021 | 3,108 | 397 | 450 | 690 | N/A |
| 12/31/2020 | 3,057 | 433 | 476 | 701 | N/A |
| 9/30/2020 | 3,022 | 424 | 400 | 627 | N/A |
| 6/30/2020 | 3,003 | 413 | 384 | 615 | N/A |
| 3/31/2020 | 3,031 | 408 | 376 | 591 | N/A |
| 12/31/2019 | 2,976 | 393 | 340 | 570 | N/A |
| 9/30/2019 | 2,898 | 336 | 347 | 573 | N/A |
| 6/30/2019 | 2,840 | 319 | 336 | 548 | N/A |
| 3/31/2019 | 2,782 | 304 | 350 | 540 | N/A |
| 12/31/2018 | 2,730 | 269 | 325 | 490 | N/A |
| 9/30/2018 | 2,696 | 316 | 314 | 467 | N/A |
| 6/30/2018 | 2,651 | 303 | N/A | 478 | N/A |
| 3/31/2018 | 2,620 | 291 | N/A | 458 | N/A |
| 12/31/2017 | 2,585 | 243 | N/A | 463 | N/A |
| 9/30/2017 | 2,570 | 144 | N/A | 453 | N/A |
| 6/30/2017 | 2,582 | 120 | N/A | 424 | N/A |
| 3/31/2017 | 2,613 | 110 | N/A | 424 | N/A |
| 12/31/2016 | 2,616 | 142 | N/A | 439 | N/A |
| 9/30/2016 | 2,588 | 167 | N/A | 364 | N/A |
| 6/30/2016 | 2,431 | 135 | N/A | 294 | N/A |
| 3/31/2016 | 2,233 | 111 | N/A | 255 | N/A |
| 12/31/2015 | 2,042 | 94 | N/A | 185 | N/A |
| 9/30/2015 | 1,897 | 113 | N/A | 221 | N/A |
| 6/30/2015 | 1,870 | 135 | N/A | 241 | N/A |
| 3/31/2015 | 1,842 | 135 | N/A | 246 | N/A |
| 12/31/2014 | 1,807 | 133 | N/A | 233 | N/A |
| 9/30/2014 | 1,739 | 123 | N/A | 234 | N/A |
| 6/30/2014 | 1,660 | 122 | N/A | 223 | N/A |
| 3/31/2014 | 1,615 | 129 | N/A | 210 | N/A |
| 12/31/2013 | 1,585 | 132 | N/A | 189 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei STE ( 11.5% per jaar) ligt boven de spaarquote ( 2.6% ).
Winst versus markt: De winst van STE ( 11.5% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.2% per jaar).
Hoge groeiwinsten: De winst van STE zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van STE ( 6% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.9% per jaar).
Hoge groei-inkomsten: De omzet van STE ( 6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen STE zal naar verwachting over 3 jaar laag zijn ( 11.6 %).